Table 1 Comparison of cardiology evaluation and cardiovascular imaging modalities in patients before/during treatment versus during survivorship care, by provider report. Patients were more likely to be evaluated by a cardiologist post-treatment or during survivorship care than prior/during cancer treatment. There was an increase in use of Cardiac MR imaging as part of survivorship care
| Cardiac Visit/Cardiac Testing |
Before/During Treatment (N = 64) |
After Treatment/Survivorship (N = 65) | P-value |
|---|---|---|---|
| Evaluation by a Cardiologist | 8 (12%) | 28 (43%) | < 0.01 |
| Electrocardiogram | 48 (75%) | 43 (66%) | 0.27 |
| Extended arrhythmia monitoring | 2 (3%) | 7 (11%) | 0.16 |
| Echocardiogram, standarda | 37 (58%) | 36 (55%) | 0.77 |
| Echocardiogram, advancedb | 32 (50%) | 35 (54%) | 0.66 |
| Cardiac magnetic resonance imaging | 2 (3%) | 11 (17%) | < 0.01 |
| Radionuclide imaging (e.g. MUGA) | 0 (0%) | 2 (3%) | 0.50 |
| Serum biomarkers | 5 (8%) | n/a | – |
| Cardiopulmonary exercise testing | n/a | 5 (8%) | – |
| None | 0 (0%) | 0 (0%) | 1.00 |
| Other/Unknown/not applicable | 9 (14%) | 8 (12%) | 0.76 |